Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00346 |
CD30/TNFRSF8 Protein, Human, Recombinant (His & Avi)
CD30KI-1,CD30L receptor,... |
Human | HEK293 Cells |
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs). | |||
TMPJ-00342 |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, His)
Lymphocyte activation antigen CD30,TNFRSF8,Tumor ne... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 60-95 KDa and the accession number is P28908. | |||
TMPJ-00341 |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, hFc)
TNFRSF8,Ki-1 antigen,CD30,CD30L <... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, hFc) is expressed in HEK293 mammalian cells with C-Fc tag. The predicted molecular weight is 90-120 KDa and the accession number is P28908. | |||
TMPJ-00340 |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, His & Avi), Biotinylated
Lymphocyte activation antigen CD30,TNFRSF8,CD |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (aa 19-379, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-6xHis-Avi tag. The predicted molecular weight is 60-90 KDa and the accession number is P28908. | |||
TMPJ-00343 |
CD30/TNFRSF8 Protein, Human, Recombinant (mFc)
TNFRSF8,Tumor necrosis factor receptor superfamily ... |
Human | HEK293 Cells |
CD30/TNFRSF8 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with C-mFc tag. The predicted molecular weight is 90-120 KDa and the accession number is P28908. |